Gene therapy to inhibit xenoantibody production using lentiviral vectors in non-human primates

Gene Therapy

Volumn 14, Issue 1, 2007, Pages 49-57

  Fischer Lougheed, J Y ^a   Tarantal, A F ^b   Shulkin, I ^a   Mitsuhashi, N ^a   Kohn, D B ^a   Lee, C C I ^b   Kearns Jonker, M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chimerism; Lentiviral vector; Primate; Rhesus monkeys; Xenotransplanation

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ALPHA 1,3 GALACTOSYLTRANSFERASE ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN M;

ANIMAL CELL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; GENE CONSTRUCT; GENE THERAPY; HEMATOPOIETIC CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; LENTIVIRUS VECTOR; LIVER CELL; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; SWINE; WHOLE BODY RADIATION; XENOTRANSPLANTATION;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; BONE MARROW TRANSPLANTATION; CHIMERA; EPITOPES; GALACTOSYLTRANSFERASES; GENE THERAPY; GENETIC VECTORS; GRAFT REJECTION; HIV-1; IMMUNOGLOBULIN M; MACACA FASCICULARIS; MODELS, ANIMAL; SIMIAN IMMUNODEFICIENCY VIRUS; SWINE; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSGENES; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; MUS; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS; SUIDAE; SUS;

EID: 33845683007     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302818     Document Type: Article

References (44)

1. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IF. Anti-pig IgM antibodies in human serum react predominantly with Galα(1-3)Gal epitopes. Proc Natl Acad Sci USA 1993; 30: 11391-11395.
2. Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 1988; 263: 17755-17762.
3. Tearle RG, Tange MJ, Zannettino ZL, Katerelos M, Shinkel TA, Van Denderen BJ et al. The alpha-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation. Transplantation 1996; 61: 13-19.
4. Thall A, Murphy H, Lowe JB. Alpha1,3-galatosyltransferase deficient mice produce cytotoxic natural antibodies. Transplant Proc 1996; 28: 561-562.
5. LaTemple DC, Galili U. Adult and neonatal anti-gal response in knock-out mice for α-1,3-galactosyltransferase. Xenotransplantation 1998; 5: 191-196.
6. Yang YG, deGoma E, Ohdan H, Bracy JL, Xu Y, Iacomini J et al. Tolerization of anti-galα1-3gal natural antibody-forming B cells by induction of mixed chimerism. J Exp Med 1998; 187: 1335-1342.
7. Ohdan H, Swenson KG, Kitamura. H, Yang YG, Sykes M. Tolerization of Galα1,3Gal-reactive B cells in pre-sensitized α1,3-galactosyltransferase-deficient mice by nonmyeloablative induction of mixed chimerism. Xenotransplantation 2001; 8: 227-238.
8. Bracy JL, Chase CM, Russell PS, Mauiyyedi S, Colvin RB, Iacomini J. Induction of molecular chimerism by gene therapy prevents antibody-mediated heart transplant rejection. Gene Therapy 2001; 8: 1738-1744.
9. + heart grafts. Transplantation 2004; 77: 1748-1754.
10. Ogawa H, Yin DP, Galili U. Induction of immune tolerance to a transplantation carbohydrate antigen by gene therapy with autologous lymphocytes transduced with adenovirus containing the corresponding glycosyltransferase gene. Gene Therapy 2004; 11: 292-301.
11. Mitsuhashi N, Fischer-Lougheed J, Shulkin I, Kleihauer A, Kohn DB, Weinberg K et al. Tolerance induction by lentiviral gene therapy with a non-myeloablative regimen. Blood 2006; 107: 2286-2293.
12. Owens CM, Yang PC, Göttlinger H, Sodroski J. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J Virol 2003; 77: 726-731.
13. Kootstra NA, Munk C, Tonnu N, Landau NR, Verma IM. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc Natl Acad Sci USA 2003; 100: 1298-1303.
14. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World Monkeys. Nature 2004; 427: 848-853.
15. Strokan V, Molne J, Svalander CT, Breimer ME. Heterogeneous expression of Gal alphal-3Gal xenoantigen in pig kidney: A lectin and immunogold electron microscopic study. Transplantation 1998; 66: 1495-1503.
16. Murphy LA, Goldstein IJ. Five alpha-D-galactopyranosyl-binding isolectins from Bandeiraea simplicifolia seeds. J Biol Chem 1977; 252: 4739-4742.
17. Laukkanen MO, Kuramoto K, Calmels B, Takatoku M, von Kalle C, Donahue RE et al. Low-dose total body irradiation causes clonal fluctuation of primate hematopoietic stem and progenitor cells. Blood 2005; 105: 1010-1015.
18. Goud SN. Effects of sublethal radiation on bone marrow cells: Induction of apoptosis; and inhibition of antibody formation. Toxicology 1999; 135: 69-76.
19. Hanawa H, Hematti P, Keyvanfar K, Metzger ME, Krouse A, Donahue RE et al. Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood 2004; 103: 4062-4069.
20. + stem cells in a nonhuman primate model. Stem Cells 2005; 23: 355-364.
21. Kawauchi M, Nakajima J, Endoh M, Oka T, Takamoto S. Ontogeny of anti-pig xenoantibody and hyperacute rejection. Transplantation 2000; 70: 686-688.
22. Donahue RE, Dunbar CE. Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells. Hum Gene Ther 2001; 12: 607-617.
23. An DS, Kung SK, Bonifacino A, Wersto RP, Metzger ME, Agricola BA et al. Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques. J Virol 2001; 75: 3547-3555.
24. Hanazono Y, Terao K, Shibata H, Nagashima T, Ageyama N, Asano T et al. Introduction of the green fluorescent protein gene into hematopoietic stem cells results in prolonged discrepancy of in vivo transduction levels between bone marrow progenitors and peripheral blood cells in nonhuman primates. J Gene Med 2002; 4: 470-477.
25. Horn PA, Morris JC, Bukovsky AA, Andrews RG, Naldini L, Kurre P et al. Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons. Gene Therapy 2002; 9: 1464-1471.
26. Hu J, Kelly P, Bonifacino A, Agricola B, Donahue R, Vanin E et al. Direct comparison of RD114-pseudotyped versus amphotropic-pseudotyped retroviral vectors for transduction of rhesus macaque long-term repopulating cells. Mol Ther 2003; 8: 611-617.
27. + progenitor cell. Mol Ther 2003; 8: 981-991.
28. Rosenzweig M, MacVittie TJ, Harper D, Hempel D, Glickman RL, Johnson RP et al. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood 1999; 94: 2271-2286.
29. + hematopoietic cells. Blood 2001; 97: 1951-1959.
30. Hematti P, Hong B-K, Ferguson C, Adler R, Hanawa H, Sellers S et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLOS Biol 2004; 2: E423.
31. Engel BC, Kohn DB, Podsakoff GM. Update on gene therapy of inherited immune deficiencies. Curr Opin Mol Ther 2003; 5: 503-507.
32. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotech 2006; 24: 687-696.
33. Yam PY, Li S, Wu J, Hu J, Zaia JA, Yee J-K. Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther 2002; 5: 479-484.
34. + cells derived from human and nonhuman primates. Blood 2002; 100: 823-832.
35. Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff JA, Hargrove P et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitve hematopoietic cells from human blood. Mol Ther 2002; 5: 242-251.
36. Logan AC, Lutzko C, Kohn DB. Advances in lentiviral vector design for gene-modification of hematopoietic stem cells, review. Curr Opin Biotechnol 2002; 13: 429-436.
37. Delenda C. Lentiviral vectors: Optimization of packaging, transduction and gene expression. J Gene Med 2004; 6: S125-S138.
38. Nègre D, Cosset FL. Vectors derived from simian immunodeficiency virus (SIV). Biochimie 2002; 84: 1161-1171.
39. Hanazono Y, Asano T, Ueda Y, Ozawa K. Genetic manipulation of primate embryonic and hematopoietic stem cells with simian lentivirus vectors. Trends Cardiovasc Med 2003; 13: 106-110.
40. Nagata M, Takahashi M, Muramatsu S, Ueda Y, Hanazono Y, Takeuchi K et al. Efficient gene transfer of a simian immunodeficiency viral vector into cardiomyocytes derived from primate embryonic stem cells. J Gene Med 2003; 5: 921-928.
41. Mangeot PE, Negre D, Dubois B, Winter AJ, Leissner P, Mehtali M et al. Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J Virol 2000; 74: 8307-8315.
42. H gene usage in rhesus monkeys and humans exposed to porcine hepatocytes. BMC Immunol 2006; 7: 3.
43. Baquerizo A, Mhoyan A, Kearns-Jonker M, Arnaout WS, Shackleton C, Busuttil RW et al. Characterization of human xenoreactive antibodies in liver failure patients exposed to pig hepatocytes after bioartificial liver treatment: An ex vivo model of pig to human xenotransplantation. Transplantation 1999; 67: 5-18.
44. Wetzsteon PJ, Head MA, Fletcher LM, Lye WC, Norman DJ. Cytotoxic flow-cytometric crossmatches (Flow-Tox): A comparison with conventional cytotoxicity crossmatch techniques. Hum Immunol 1992; 35: 93-99.